Brought to you by 
Dermatology-focused Evolus nets $55.8mm in Nasdaq IPO
Feb 2018
Executive Summary
Medical aesthetics company Evolus Inc. (neurotoxin development and manufacturing) netted $55.8mm in its initial public offering of 5mm shares at $12, the low end of its anticipated $12-14 range.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dermatology-focused Evolus nets $55.8mm in Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice